Literature DB >> 15641134

Purification and application of C-terminally truncated hepatitis C virus E1 proteins expressed in Escherichia coli.

Jing Liu1, Li-Xin Zhu, Yu-Ying Kong, Guang-Di Li, Yuan Wang.   

Abstract

AIM: To explore the possibility of expressing hepatitis C virus (HCV) envelope protein 1 (E1) in Escherichia coli (E. coli) and to test the purified recombinant E1 proteins for clinical and research applications.
METHODS: C-terminally truncated E1 fragments were expressed in E. coli as hexa-histidine-tagged fusion proteins. The expression products were purified under denaturing conditions using immobilized-metal affinity chromatography. Purified E1 proteins were used to immunize rabbits. Rabbit anti-sera thus obtained were reacted with both E. coli- and mammalian cell-expressed E1 glycoproteins as detected by Western blot.
RESULTS: Full-length E1 protein proved difficult to express in E. coli. C-terminally truncated E1 was successfully expressed in E. coli as hexa-histidine-tagged recombinant fusion protein and was purified under denaturing conditions on Ni(2+)-NTA agarose. Rabbit anti-sera raised against purified recombinant E1 specifically reacted with mammalian cell-expressed E1 glycoproteins in Western blot. Furthermore, E. coli-derived E1 protein was able to detect animal antibodies elicited by E1-based DNA immunization.
CONCLUSION: These results demonstrate that the prokaryotically expressed E1 proteins share identical epitopes with eukaryotically expressed E1 glycoprotein. The E. coli-derived E1 proteins and corresponding antisera can become useful tools in anti-HCV vaccine research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15641134      PMCID: PMC4250799          DOI: 10.3748/wjg.v11.i4.503

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  The scientific challenge of hepatitis C.

Authors:  J Cohen
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

Review 2.  Advances in therapy for hepatitis C infection.

Authors:  Claudia O Zein; Nizar N Zein
Journal:  Microbes Infect       Date:  2002-10       Impact factor: 2.700

3.  Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.

Authors:  L M Lagging; K Meyer; R J Owens; R Ray
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

5.  Prevalence, genotypes, and an isolate (HC-C2) of hepatitis C virus in Chinese patients with liver disease.

Authors:  Y Wang; H Okamoto; F Tsuda; R Nagayama; Q M Tao; S Mishiro
Journal:  J Med Virol       Date:  1993-07       Impact factor: 2.327

6.  Overcoming the toxicity of membrane peptide expression in bacteria by upstream insertion of Asp-Pro sequence.

Authors:  Cédric Montigny; François Penin; Claire Lethias; Pierre Falson
Journal:  Biochim Biophys Acta       Date:  2004-01-28

7.  Natural history of acute symptomatic hepatitis type C.

Authors:  M Wawrzynowicz-Syczewska; J Kubicka; Z Lewandowski; A Boroń-Kaczmarska; M Radkowski
Journal:  Infection       Date:  2004-06       Impact factor: 3.553

8.  Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry.

Authors:  Miriam Triyatni; Bertrand Saunier; Padma Maruvada; Anthony R Davis; Luca Ulianich; Theo Heller; Arvind Patel; Leonard D Kohn; T Jake Liang
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more
  3 in total

1.  Establishment of stable Huh-7 cell lines expressing various hepatitis C virus genotype 3a protein: an in-vitro testing system for novel anti-HCV drugs.

Authors:  Sadia Butt; Muhammad Idrees; Irshad-Ur Rehman; Liaqat Ali; Abrar Hussain; Muhammad Ali; Naveed Ahmed; Sana Saleem; Madiha Fayyaz
Journal:  Genet Vaccines Ther       Date:  2011-06-28

Review 2.  The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.

Authors:  Siobhán B Cashman; Brian D Marsden; Lynn B Dustin
Journal:  Front Immunol       Date:  2014-11-10       Impact factor: 7.561

Review 3.  Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.

Authors:  Giuseppe Sautto; Alexander W Tarr; Nicasio Mancini; Massimo Clementi
Journal:  Clin Dev Immunol       Date:  2013-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.